Anika Therapeutics | ANIK - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Abbott USD 3.6B 330M 2026-06
Agenus USD 6.21M 4.34M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Halozyme Therapeutics USD 57M 10.71M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.47M 208K 2026-06
Integra LifeSciences USD 166.22M 12.01M 2026-06
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.25B 168M 2026-09
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Merit Medical Systems USD 129.23M 18.76M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.63B 307M 2026-06
Smith & Nephew USD 1.45B 29M 2026-06
Stryker USD 2.12B 32M 2026-06
Veracyte USD 55.71M 4.87M 2026-06
Xencor USD 77.54M 4.59M 2026-06
Zimmer Biomet Holdings USD 911.6M 61.7M 2026-06